EP0384752A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Milled proteins
Assignee: Eli Lilly and Co
•
Filing: 1990-02-22
•
Granted: —
•
Expires: 2010-02-22
Abstract
Abstract The particle size of amorphous protein material is reduced to uniform particulates without protein decomposition or loss of activity by passing the material through a fluid-energy mill.
Inventors
- 👤 William Webster Thompson
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-25 06:16
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/27
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
21 words
A process for reducing the particle size of a amorphous protein material which comprises passing the material through a fluid-energy mill.
Claim 2
Dependent Claim
21 words
A process for reducing the particle size of a amorphous protein material which comprises passing the material through a fluid-energy mill.
Claim 3
Dependent Claim
12 words
The process of claim 1 wherein the protein material is bovine somatotropin.
Claim 4
Dependent Claim
14 words
The process of claim 1 wherein the protein material is growth hormone releasing factor.
Claim 5
Dependent Claim
42 words
The process of claim 1 wherein the fluid-energy mill is one of the class wherein the fluid energy is admitted in fine high velocity streams at an angle around a portion or all of the periphery of a grinding or classifying chamber.
Claim 6
Dependent Claim
33 words
The process of claim 1 wherein the fluid-energy mill is one of the class wherein fluid streams convey the particles at high velocity into a chamber where two streams impact upon each other.
Claim 7
Dependent Claim
10 words
Milled bovine somatotropin prepared by the process of claim 1.
Claim 8
Dependent Claim
44 words
A process for formulating a protein material as a parenteral product, which comprises a) reducing the average particle size of the protein material by passing the material through a fluid-energy mill, and (b) admixing the milled material with a pharmacologically acceptable carrier or diluent.
Claim 9
Dependent Claim
44 words
A process for formulating a protein material as a parenteral product, which comprises a) reducing the average particle size of the protein material by passing the material through a fluid-energy mill, and (b) admixing the milled material with a pharmacologically acceptable carrier or diluent.
Claim 10
Dependent Claim
10 words
A parenteral product produced by the process of claim 7.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.